News
FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s ...
As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...
A Massachusetts biotechnology company is laying off nearly 500 employees, more than a third of its total workforce, as it faces pushback from the U.S. Food and Drug Administration on one of its ...
The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...
The layoffs followed a March announcement by Health Secretary Robert F. Kennedy Jr., who called for a major department overhaul.
An estimated 53 drugs would not enter the market in the next 30 years if the NIH is hit with a permanent 10% budget cut and the FDA experiences a nine-month drug review delay due to staffing cuts, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results